卵巢上皮性癌占卵巢惡性腫瘤85%～90%，由于缺乏有效的早期診斷和發(fā)現(xiàn)的方法，75%的患者就診時已屬晚期。血清學(xué)標(biāo)志物以其檢測方便、利于大規(guī)模篩查的優(yōu)勢在卵巢上皮性癌的早期診斷中起著重要作用。近幾年眾多學(xué)者對其進行了廣泛深入研究，發(fā)現(xiàn)許多腫瘤標(biāo)志物與卵巢上皮性癌密切相關(guān)，如CA125、HE4、TGF-β1、β2-MG、YKL-40、lyGDⅠ、hK6、hK10、bcl-2、HMGB1、Notch3、P-選擇素和腫瘤自身抗體等。尋找特異度、敏感度高的腫瘤標(biāo)志物，發(fā)展以血清學(xué)為基礎(chǔ)的篩選方法，對于提高卵巢癌早期診斷水平，改善治療效果、降低卵巢癌患者的病死率具有重要意義。

Epithelial ovarian cancer is the most common form of ovarian cancers accounting for 85%—90%. Due to the lack of effective screening strategies and the absence of symptoms in early-stage of disease, 75% of cases have developed to an advanced stage at the time of primary diagnosis. Serological markers are convenient to detect and easy to mass screening as well as play an important role in epithelial oarian cancer early diagnosis. Extensive researches showed that many of the tumor markers are closely related to epithelial ovarian cancer, such as CA125, HE4, TGF-β1, β2-MG, YKL-40, lyGD Ⅰ, hK6, hK10, bcl-2, HMGB1, Notch3, P-choose element, and tumor autoantibody, etc. To look for specific and high sensitivity tumor markers, screening method based on serology could improve ovarian cancer early diagnosis level, promote the treatment effect, and reduce the mortality of patients with ovarian cancer..